BioMimetix is developing a new class of oncology therapeutics, redox active metalloporphyrins, for the treatment of cancer patients.
The drugs are uniquely potent with activity in tumor inhibition and normal tissue protection.
The drugs are uniquely potent with activity in tumor inhibition and normal tissue protection.